Journal Home
Search for

Volume 11, Issue 2, Pages 149-159 (February 2010)


View previous. 9 of 17 View next.

A Prolonged Protein Kinase C-Mediated, Opioid-Related Antinociceptive Effect of St John's Wort in Mice

Nicoletta GaleottiCorresponding Author Informationemail address, Elisa Vivoli, Anna Rita Bilia, Maria Camilla Bergonzi, Alessandro Bartolini, Carla Ghelardini

Received 10 February 2009; received in revised form 18 May 2009; accepted 24 June 2009. published online 30 November 2009.

Abstract 

The antinociceptive profile of St. John's Wort (SJW) was investigated in mice in a condition of acute thermal and chemical pain, together with the mechanism that might underlie this effect. A dried extract of SJW induced a prolonged antinociception that persisted for 120 minutes after administration. The thermal antinociception was prevented by naloxone and by the protein kinase C (PKC) activator PMA, whereas the chemical antinociception was prevented by PMA, remaining naloxone insensitive. A chloroform (CHL) and a methanol (MET) fraction, obtained to investigate the involvement of the SJW main components, hyperforin and hypericin/flavonoid, respectively, increased pain threshold with a time course comparable to the dried extract. The CHL antinociception was prevented by naloxone, whereas the MET antinociception was antagonized by PMA. Purified hyperforin and hypericin showed an antinociceptive efficacy comparable to CHL and MET, respectively. Conversely, flavonoids were devoid of any effect. The administration of yohimbine and atropine did not modify SJW, CHL and MET antinociception. These results indicate that both CHL and MET fractions mediate the SJW-induced antinociception. In particular, the presence of hypericin was fundamental to induce both thermal and chemical antinociception through the inhibition of the PKC activity, whereas hyperforin selectively produced a thermal opioid antinociception.

Perspective

This article presents evidence of a persistent thermal and chemical antinociception of SJW that is mainly mediated by PKC-inhibiting mechanisms. These findings identify important targets for a longer-acting activation of endogenous pain systems and should potentially help clinicians who seek safe, tolerable, and prolonged treatments for pain relief.

 Department of Preclinical and Clinical Pharmacology, University of Florence, Viale G. Pieraccini 6, I-50 139 Florence, Italy

 Department of Pharmaceutical Sciences, University of Florence, via U. Schiff 6, 50019 Sesto Fiorentino, Florence, Italy

Corresponding Author InformationAddress reprint requests to: Dr. Nicoletta Galeotti, Dept. of Pharmacology, Viale G. Pieraccini 6, I-50139 Florence, Italy.

 This work was supported by grants from MIUR.

PII: S1526-5900(09)00610-5

doi:10.1016/j.jpain.2009.06.013


View previous. 9 of 17 View next.